Novartis

Novartis Indonesia

Novartis works with the patient community around the world to discover new ways to improve and extend people’s lives. Novartis works closely with healthcare professionals around the world to support ...
Novartis

Career Search

Explore opportunities with Novartis and Sandoz below. For additional roles with Novartis Gene Therapies (formerly AveXis) visit the GTx Career Search.
Novartis

A Phase III Study to Investigate Efficacy, Safety and Tolerability of Iptacopan Compared With Placebo in Participants Aged 18 to 75 Years With gMG.

All compounds are either investigational or being studied for (a) new use(s). Efficacy and safety have not been established. There is no guarantee that they will become commercially available for the ...
Novartis

Country Leadership Team

Novartis in Slovenia Country President and Novartis Pharma Services Inc., Branch Office General Manager ...
Novartis

Novartis showcases significant immunology advancements in ACR congress with new data in complex autoimmune diseases

About Novartis Immunology At Novartis, we’re advancing bold science for autoimmune diseases, where meaningful therapeutic progress has long stalled. With a growing legacy of first-in-class innovation ...
Novartis

Novartis receives FDA approval for Rhapsido® (remibrutinib), the only oral, targeted BTKi treatment for chronic spontaneous urticaria (CSU)

Ad hoc announcement pursuant to Art. 53 LR Rhapsido helps to inhibit release of histamine and proinflammatory mediators by targeting BTK, offering unique approach to CSU treatment1 Well-controlled ...
Novartis

Novartis announces mutual agreement to terminate sale of Sandoz US generic oral solids, dermatology portfolio to Aurobindo

Basel, April 2, 2020 – Novartis today announced the mutual agreement with Aurobindo Pharma USA Inc. to terminate the agreement to sell the Sandoz US generic oral solids and dermatology businesses to ...
Novartis

Novartis ianalumab Phase III trial meets primary endpoint in ITP, demonstrating statistically significant improvement in time to treatment failure

Ianalumab prolonged the duration of safe platelet levels during and after treatment in patients with primary immune thrombocytopenia (ITP) previously treated with corticosteroids 1,2 Patients treated ...
Novartis

Novartis completes acquisition of Tourmaline Bio

. Novartis is providing the information in this press release as of this date, and Novartis does not undertake any obligation to update any forward-looking statements contained in this press release ...
Novartis

Novartis opens facility for innovative cell and gene therapies in Switzerland

In the presence of Federal Councillor Alain Berset and other distinguished guests, Novartis inaugurated a new manufacturing facility for cell and gene therapies at Stein, Switzerland on November 28th.
Novartis

Novartis agrees to acquire Avidity Biosciences, an innovator in RNA therapeutics, strengthening its late-stage neuroscience pipeline

Basel, October 26, 2025 – Novartis today announced that it has entered into an agreement to acquire Avidity Biosciences, Inc. (Nasdaq: RNA), a San Diego-based, biopharmaceutical company focused on a ...
Novartis

Novartis provides update on production of radioligand therapy medicines

Novartis has temporarily suspended production of Lutathera® and Pluvicto™/ 177Lu-PSMA-617 at facilities in Ivrea, Italy and Millburn, New Jersey This action has been taken out of an abundance of ...